Abstract: Glucagon analogs characterized principally by the removal of the 9-aspartic acid residue or its replacement with an amino acid residue other than an L- dibasic amino acid containing up to five carbon atoms with or without a histidine at the amino terminal are useful adjuncts to insulin therapy.

Abstract: Vasoactive intestinal peptide analogs containing substitutions of appropriately selected amino acids at specific positions of the VIP molecule.

Abstract: The present invention provides novel methods for the treatment of retroviral infection, particularly HIV disease. According to the present invention, human HIV infected hosts were selected who had been on a stable dose of an anti-retroviral agent, such as zidovudine, for up to two years prior to administration of the ribosomal inhibiting protein trichosanthin, and who had failed anti-retroviral therapy, as manifest by decrease in CD4+ cells on at least two serial measurements, or loss of over 50 CD4+ cells/mm.sup.3 /year. These patients remained on the same dose of anti-retroviral agent (AZT or ddI) and received trichosanthin, 1.2 mg weekly, then monthly. A significant number of patients demonstrated improved CD4+ cell counts following administration of trichosanthin as compared to CD4+ cell counts prior to adminstration of the drug.

Abstract: Structures containing a dielectric material having a polymeric reactive ion etch barrier embedded therein. The preferred dielectric materials are polymers, preferably polyimide materials. The RIE etch barrier is a copolymer having an aromatic component having high thermal stability and having a cross-linking component selected from metallacyclobutane, metallabutene and vinyl groups. The etch barrier is deposited as a solvent free liquid which can fill gaps between the dielectric material and electrical conductors embedded therein. The liquid polymer is cured to a solid insoluble state. The structures with electrical conductors embedded therein are useful for electronic applications.

Abstract: A novel pentadecapeptide is disclosed which is useful for the control of intestinal fluid absorption and that has the following amino acid sequence ##STR1##

Abstract: Mixtures of different pesticides, in emulsion and suspension form respectively, are stabilized by incorporation in the mixture of the emulsion and suspension a dispersant capable of being strongly adsorbed onto the particles of the pesticide in suspension form, such a dispersant being a block of graft copolymer as described in UK Patent Specification Number 2026341-A and/or 1196248.

Abstract: The present invention provides a method for preparing aqueous formulations of thymopentin, which method permits the peptide to retain its biological activity during storage at room temperature.

Abstract: The present invention relates to novel LHRH analogs. The LHRH analogs include "pseudo" hexapeptide, heptapeptide, octapeptide and nonapeptide analogs of LHRH, wherein all or some of the amino acids, 1, 2 and 3 have been eliminated and the remaining (2-9), (2-10), (3-9), (3-10), (4-9) or (4-10) peptide is linked to various carboxylic acids which take the place of amino acids 1, 2 or 3 in LHRH.

Abstract: The invention relates to cyclopeptide derivative usable as protease inhibitors and complying with formula: ##STR1## in which R.sup.1 is a halogen atom, e.g. bromine or a radical such as S.sup.+ R.sub.2.sup.4 X.sub.1/v.sup.v-, R.sup.2 is a hydrogen atom, an alkyl radical, a halogen atom or other groups, R.sup.3 is NH, O or S, Z comprises a peptide sequence Z.sup.1 and a group such that CO has one end connected to the aromatic nucleus and CO-AA is a radical derived fropm an amino acid having a specificity with respect to the protease to be inhibited.

Abstract: A method of fractionating plasma protein which comprises treating a plasma protein-containing material in the following sequence of steps, provided that steps (ii) through (v) may be performed in an optional order: (i) freeze-thaw treatment, (ii) treatment at 5 to 10% ethanol concentration, (iii) treatment with an anion exchanger, (iv) affinity chromatography with immobilized lysine, (v) affinity chromatography with immobilized heparin, (vi) treatment at 18 to 30% ethanol concentration, (vii) treatment at 35 to 45% ethanol concentration.

Abstract: A method is provided for the treatment of grafts such as tissue or organs prior to transplantation into a suitable host. The grafts are incubated, coated, or perfused with TGF-.beta. for an effective time for the uptake of the agent into the grafts and induction of its biological effects. The thus-treated graft is then transplanted into a compatible host, preferably a human host.

Abstract: A process for removing toxins from solutions of proteins, in which an aqueous solution of a protein which contains a buffer substance, a chelating agent and a detergent is subjected to an ion exchange chromatography, is described.

Abstract: Novel peptides having substantially the amino acid sequence:X-Gly-Asn-Gly-Asp-Glu-Gln-Pro-Leu-Thr-Y,where X is H, a single amino acid or a short-chain peptide and Y is OH, NH.sub.2, a single aminoacid or a short-chain peptide. These peptides have natriuretic and diuretic activity.

Abstract: This invention relates to a method of isolating and purifying proteins such as fibroblast growth factor using metal chelate affinity column chromatography and without the use of heparin. Also disclosed is a method of recovering bFGF multimers and purifying bFGF using metal chelate affinity column chromatography in the absence of heparin.

Abstract: Bacteriocin compositions comprising lanthionine containing bacteriocins and non-bactericidal agents. When the bacteriocin compositions are combined with a suitable carrier with each component present in sufficient quantities such that the composition is effective against Gram negative bacteria in addition to Gram positive bacteria, they become enhanced, rapid acting, broad range bactericides suitable for a variety of applications.

Abstract: The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose expression is stimulated by NGF, such as .beta.-protein precursor and prion proteins, which proteins or their products are associated with neurodegenerative disorders, whereas the NGF agonist peptides can be used to treat neoplastic disorders such as neuroblastomas.

Abstract: A magnetic storage medium is composed of a non-wettable substrate upon which a transient liquid metal layer is deposited and maintained as a distribution of discontinuous liquid features. A magnetic film layer is deposited on the transient liquid metal layer resulting in a reaction of the liquid metal with the magnetic film. The topology of the magnetic film is controllable by adjusting the thickness of the transient liquid metal layer.

Abstract: There is disclosed an adsorbent, comprising a carrier on which is immobilized a peptide possessing an ability to bind to the human antibody to the nicotinic acetylcholine receptor and represented by the formula:H--X--A--Y--Zwherein A stands for a peptide residue, one of X and Y stands for a single bond, an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR1## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and the other of X and Y stands for an amino acid residue selected from the class consisting of Asp, Glu, Lys and a divalent group represented by the formula, ##STR2## (wherein n stands for an integer in the range of 1 to 17), or a peptide residue formed by peptide linkage of two to ten amino acid residues of at least one species selected from the class mentioned above and Z stand

Abstract: In vitro results indicate that trimethoprim may be ineffective against S. enteritides. However, in vivo results show that trimethoprim alone and in combination with polymyxin B sulfate is effective on S. enteritidis infections in poultry.

Abstract: A magnetic recording medium comprises a substrate and provided on at least one side thereof a magnetic recording layer and a protective layer of thin film mainly composed of an oxide of silicon, in this order. Said protective layer has an electrical specific resistance of not less than 10.sup.12 .OMEGA.. cm.